Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

N R Waugh, E Cummins, P L Royle, C Clar, M Marien, B Richter, S Philip

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

In May 2008, the National Institute for Health and Clinical Excellence (NICE) issued an updated guideline [clinical guideline (CG) 66] for the management of all aspects of type 2 diabetes. This report aims to provide information on new drug developments to support a 'new drugs update' to the 2008 guideline.
Original languageEnglish
Pages (from-to)1-248
Number of pages248
JournalHealth Technology Assessment
Volume14
Issue number36
DOIs
Publication statusPublished - Jul 2010

Keywords

  • adamantane
  • body weight
  • cost-benefit analysis
  • diabetes mellitus, type 2
  • dipeptidyl-peptidase IV inhibitors
  • glucagon-like peptide 1
  • Great Britain
  • hemoglobin A, glycosylated
  • humans
  • hypoglycemic agents
  • insulin
  • nitriles
  • peptides
  • pyrazines
  • pyrrolidines
  • quality of life
  • randomized controlled trials as topic
  • state medicine
  • thiazolidinediones
  • triazoles
  • venoms

Fingerprint Dive into the research topics of 'Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation'. Together they form a unique fingerprint.

  • Cite this